European Commission Grants Marketing Authorisation for Zebinix® (eslicarbazepine acetate) for the Treatment of Partial-Onset Seizures in Children - Seite 3

employees working across our global network of R&D facilities,
manufacturing sites and marketing subsidiaries, we strive to realise
our hhc philosophy by delivering innovative products in multiple
therapeutic areas with high unmet medical needs, including Oncology
and Neurology.

As a global pharmaceutical company, our mission extends to
patients around the world through our investment and participation in
partnership-based initiatives to improve access to medicines in
developing and emerging countries.

For more information about Eisai Co Ltd, please visit
http://www.eisai.com

References



1. European Commission: Community register of medicinal products for
human use. Product Information - Zebinix. Available at:
http://ec.europa.eu/health/documents/community-register/html/h514.htm
Last updated December 2016

2. Zebinix SMPC, Available at http://www.ema.europa.eu/docs/en_GB/do
cument_library/EPAR_-_Product_Information/human/000988/WC500047225.pd
f Last updated: May 2016

3. Moreira J, et al. J Neurol Sci 2015;357:e432-456 (abstract 1513;
WFN15-1735; e439)

4. Hebeisen S, et al. Eslicarbazepine and the enhancement of slow
inactivation of voltage-gated sodium channels: a comparison with
carbamazepine, oxcarbazepine and lacosamide. Neuropharmacology 2015;
89:122-35

5. Soares-da-Silva P, et al. Eslicarbazepine acetate for the
treatment of focal epilepsy: an update on its proposed mechanisms of
action. Pharmacol Res Perspect. 2015; 3:e00124

6. Elger C, et al. Eslicarbazepine acetate: A double-blind, add-on,
placebo-controlled exploratory trial in adult patients with
partial-onset seizures. Epilepsia 2007; 48:497-504

7. Elger C, et al. Efficacy and safety of eslicarbazepine acetate as
adjunctive treatment in adults with refractory partial-onset
seizures: A randomised, double-blind, placebo-controlled,
parallel-group phase III study. Epilepsia. 2009;50:454-63

8. Ben-Menachem E, et al. Eslicarbazepine acetate as adjunctive
therapy in adult patients with partial epilepsy. Epilepsy Res.
2010;89(2-3):278-85

9. Gil-Nagel A, et al. Efficacy and safety of 800 and 1200 mg
eslicarbazepine acetate as adjunctive treatment in adults with
refractory partial-onset seizures. Acta Neurol Scand. 2009;
120:281-87

10. Epilepsy in the WHO European Region: Fostering Epilepsy Care in
Europe. Available at:
http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510.pdf
Accessed November 2016

11. Pugliatti M, et al. Estimating the cost of epilepsy in Europe: A
review with economic modeling. Epilepsia 2007:48(12):2224-33

12. Forsgren L, et al. The epidemiology of epilepsy in Europe - a
systematic review. Eur J Neurol. 2005; 12(4):245-53

December 2016

Zebinix-EU0112

ots Originaltext: Eisai
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Bial: Susana Vasconcelos
[phone] / [phone]
[e-mail]

Eisai: Cressida Robson
[phone]
[e-mail]

Tonic Life Communications: Carys Thomas Ampofo / Stan Jackson
[phone] /[phone]
[e-mail] [e-mail]